EPS for MetLife, Inc. (MET) Expected At $1.18

April 17, 2018 - By Kurt Siggers

MetLife, Inc. (NYSE:MET) LogoInvestors sentiment increased to 1.02 in 2017 Q4. Its up 0.13, from 0.89 in 2017Q3. It improved, as 45 investors sold MetLife, Inc. shares while 330 reduced holdings. 93 funds opened positions while 290 raised stakes. 782.94 million shares or 0.24% less from 784.85 million shares in 2017Q3 were reported.
Btc Cap Management Incorporated, a Iowa-based fund reported 67,833 shares. Cullinan Assoc has invested 0.43% of its portfolio in MetLife, Inc. (NYSE:MET). Pacific Glob Inv Mgmt holds 88,598 shares. Dekabank Deutsche Girozentrale owns 300,272 shares for 0.11% of their portfolio. Tompkins Financial Corporation, a New York-based fund reported 3,816 shares. Mufg Americas reported 0.02% of its portfolio in MetLife, Inc. (NYSE:MET). Winfield Associate, a Ohio-based fund reported 320 shares. Bank Of Montreal Can, a Ontario – Canada-based fund reported 1.73 million shares. At Commercial Bank invested in 11,378 shares or 0.06% of the stock. Essex Svcs holds 5,930 shares. Regent Investment Mgmt Limited Liability Co reported 0.32% in MetLife, Inc. (NYSE:MET). Kanawha Cap Limited Liability invested in 0.4% or 53,881 shares. Wagner Bowman Mngmt Corporation has 15,965 shares. Ironwood Ltd Liability Corp reported 0% of its portfolio in MetLife, Inc. (NYSE:MET). Wealthtrust accumulated 160 shares or 0% of the stock.

Analysts expect MetLife, Inc. (NYSE:MET) to report $1.18 EPS on May, 2.They anticipate $0.28 EPS change or 19.18 % from last quarter’s $1.46 EPS. MET’s profit would be $1.22 billion giving it 9.98 P/E if the $1.18 EPS is correct. After having $1.11 EPS previously, MetLife, Inc.’s analysts see 6.31 % EPS growth. The stock decreased 0.60% or $0.29 during the last trading session, reaching $47.1. About 1.74M shares traded. MetLife, Inc. (NYSE:MET) has declined 1.24% since April 17, 2017 and is downtrending. It has underperformed by 12.79% the S&P500.

MetLife, Inc. (NYSE:MET) Ratings Coverage

Among 10 analysts covering MetLife (NYSE:MET), 6 have Buy rating, 0 Sell and 4 Hold. Therefore 60% are positive. MetLife had 17 analyst reports since October 18, 2017 according to SRatingsIntel. Morgan Stanley maintained the shares of MET in report on Monday, November 13 with “Equal-Weight” rating. RBC Capital Markets maintained the shares of MET in report on Friday, November 3 with “Buy” rating. UBS maintained the stock with “Neutral” rating in Friday, March 2 report. The stock of MetLife, Inc. (NYSE:MET) earned “Overweight” rating by Atlantic Securities on Monday, March 26. On Friday, November 10 the stock rating was downgraded by Sandler O’Neill to “Hold”. Bank of America initiated it with “Hold” rating and $5000 target in Monday, March 26 report. Argus Research maintained it with “Buy” rating and $60 target in Monday, November 6 report. The rating was maintained by Sandler O’Neill with “Hold” on Thursday, February 15. Keefe Bruyette & Woods maintained MetLife, Inc. (NYSE:MET) on Thursday, December 21 with “Buy” rating. Wells Fargo maintained it with “Buy” rating and $60.0 target in Thursday, March 15 report.

MetLife, Inc., through its subsidiaries, provides life insurance, annuities, employee benefits, and asset management products in the United States, Japan, Latin America, Asia, Europe, and the Middle East. The company has market cap of $48.83 billion. It operates in six divisions: U.S.; Asia; Latin America; Europe, the Middle East, and Africa; MetLife Holdings; and Brighthouse Financial. It has a 13.03 P/E ratio. The firm offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, and critical illness insurance products; vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only and private floating rate funding agreements; and account guaranteed, separate account guaranteed, and trust guaranteed interest contracts.

MetLife, Inc. (NYSE:MET) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: